...
首页> 外文期刊>BMC Nephrology >Physical performance and protein-energy wasting in patients treated with nocturnal haemodialysis compared to conventional haemodialysis: protocol of the DiapriFIT study
【24h】

Physical performance and protein-energy wasting in patients treated with nocturnal haemodialysis compared to conventional haemodialysis: protocol of the DiapriFIT study

机译:与常规血液透析相比,夜间血液透析治疗的患者的身体表现和蛋白质能量浪费:DiapriFIT研究方案

获取原文
           

摘要

Background Poor physical performance and protein-energy wasting (PEW) are health issues of major concern in haemodialysis patients. The conventional haemodialysis (CHD) regime, three times per week 3–5 h, is subject of discussion because of high morbidity and mortality rates. When patients switch from CHD to longer dialysis sessions, i.e. nocturnal haemodialysis (NHD), improvement in protein intake and increase in body weight is seen. However, it is unclear whether physical performance and more important aspects of PEW, such as body composition, improve as well. Therefore, the aim of this study is to investigate whether physical performance improves and PEW decreases, when patients switch from CHD to NHD. A second aim is to assess the influence of NHD on the biomarkers fibroblast growth factor-23 and sclerostin which are thought to be associated with malnutrition and mortality in patients on haemodialysis. Methods This study is a prospective multicentre cohort study with an inclusion aim of 50 patients: 25 patients in a control group (three times per week, 3–5 h CHD) and 25 patients in a nocturnal group (three times per week, 7–9 h NHD). Primary outcome is change in physical performance, measured by the Short Physical Performance Battery. Additional measurements are a 6-min walk test, handgrip strength, a physical activity questionnaire and physical activity monitoring. The secondary outcome of the study is PEW, which will be evaluated by body weight, dual-energy X-ray absorptiometry, bio-electrical impedance spectroscopy, mid-upper arm muscle circumference, subjective global assessment, visual analogue scale for appetite and dietary records. Laboratory measurements including fibroblast growth factor-23 and sclerostin, and quality of life assessed with the Kidney Disease Quality of Life-Short Form are also studied. In every patient, four repeated measurements will be performed during one year of follow-up. Discussion This study will investigate whether physical performance improves and PEW decreases when patients switch from CHD to NHD, compared to a control group who continue treatment with CHD. Strengths of this study are the comparison with a conventional haemodialysis cohort, and the broad variety of objective measurements combined with patient-reported outcomes of physical performance and PEW. Trial registration NTR4715 , Netherlands Trial Register. Registered 30 July 2014.
机译:背景技术身体状况不佳和蛋白质能量浪费(PEW)是血液透析患者最关注的健康问题。由于较高的发病率和死亡率,传统的血液透析(CHD)方案每周3至5小时进行3次讨论。当患者从冠心病转向更长的透析时间(即夜间血液透析(NHD))时,蛋白质摄入量会增加,体重也会增加。但是,尚不清楚物理性能和PEW的更重要方面(例如身体组成)是否也有所改善。因此,本研究的目的是研究当患者从冠心病转为NHD时,身体机能是否得到改善而PEW下降。第二个目的是评估NHD对生物标志物成纤维细胞生长因子23和硬化蛋白的影响,认为这与血液透析患者的营养不良和死亡率有关。方法本研究是一项前瞻性多中心队列研究,纳入目标为50例患者:对照组25例(每周3次,CHD 3至5小时)和夜间组25例(每周3次,每周7次,CHD) NHD 9小时)。主要结果是身体机能的变化,由短期身体机能电池来衡量。其他测量包括6分钟的步行测试,握力,体力活动问卷和体力活动监测。该研究的次要结果是PEW,将通过体重,双能X射线吸收法,生物电阻抗光谱法,上臂中上肌围度,主观整体评估,食欲视觉模拟量表和饮食记录进行评估。还研究了实验室测量结果,包括成纤维细胞生长因子23和硬化蛋白,以及用肾脏疾病生命短寿质量评估表评估的生活质量。在每一年的随访中,将对每位患者进行四次重复测量。讨论:与继续接受冠心病治疗的对照组相比,该研究将调查当患者从冠心病转为NHD时,身体机能是否得到改善以及PEW降低。这项研究的优势是与常规血液透析队列的比较,以及广泛的客观测量结果以及患者报告的身体表现和PEW结果。试用注册号NTR4715,荷兰试用注册号。 2014年7月30日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号